

Research Ethics Committee Reference Number	Integrated Research Application System (IRAS) number	Name of Trial	Target number of patients agreed?	Min. number of patients agreed	Max. number of patients agreed	Target date to recruit patients agreed?	Date agreed to recruit target number of patients	Total number of patients recruited at the agreed target date	Total number of study participants recruited	Date that the trial closed to recruitment	Reason for closure of trial	Comments
14/SC/0032	142458	PHASE 3 MULTI CENTER, DOUBLE BLIND, RANDOMIZED, PLACEBO CONTROLLED, PARALLEL GROUP EVALUATION OF THE EFFICACY, SAFETY, AND TOLERABILITY OF PF 04950615, IN REDUCING THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN HIGH RISK SUBJECTS	Number agreed	5	5	Not Available / Not Agreed			4	21/07/2016	Recruitment Finished	Competitive recruitment across sites.
16/LO/0553	194625	A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER LONG-TERM SAFETY AND TOLERABILITY STUDY OF ETC 1002 IN PATIENTS WITH HYPERLIPIDEMIA AT HIGH CARDIOVASCULAR RISK WHO ARE NOT ADEQUATELY CONTROLLED BY THEIR LIPID-MODIFYING THERAPY	Number agreed	8	8	Not Available / Not Agreed			11	20/01/2017	Recruitment Finished	Exceeded recruitment target.
15/YH/0535	190077	A multicenter, randomized, open label, parallel group study comparing pre-discharge and post-discharge treatment initiation with LCZ696 in heart failure patients with reduced ejection fraction hospitalized for an acute decompensation event (ADHF) (the TRANSITION study)	Number agreed	5	5	Date Agreed	10/01/2018	0	0	16/03/2017	Withdrawn By Host	Over 80 patients pre-screened for the study however the large majority of patients have been ineligible. Of the five eligible patients all declined to take part in the study owing to not wanting to travel back and forth to hospital every 2 weeks.